A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)
FURMO-002
Phase 1 other active
Quick answer
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER) for Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations is a Phase 1 program (other) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ArriVent BioPharma
- Indication
- Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
- Phase
- Phase 1
- Modality
- other
- Status
- active